Stockscreener 앱 받기
121.13
1.60%
-1.97
시간 외 거래:
121.13
전일 마감가:
$123.10
열려 있는:
$122.18
하루 거래량:
784.29K
Relative Volume:
0.73
시가총액:
$6.83B
수익:
$738.26M
순이익/손실:
$48.89M
주가수익비율:
140.12
EPS:
0.8645
순현금흐름:
$91.69M
1주 성능:
+5.16%
1개월 성능:
+3.35%
6개월 성능:
-26.60%
1년 성능:
+2.16%
1일 변동 폭
$119.21
$122.41
1주일 범위
$112.00
$126.68
52주 변동 폭
$100.99
$175.77
Repligen Corp Stock (RGEN) Company Profile
명칭
Repligen Corp
전화
(781) 449-9560
주소
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
121.13 | 6.94B | 738.26M | 48.89M | 91.69M | 0.8645 |
ISRG
Intuitive Surgical Inc
|
402.30 | 146.01B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.43 | 40.04B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.28 | 32.04B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.19 | 30.23B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
182.82 | 27.04B | 5.54B | 1.52B | 1.74B | 10.37 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-01 | 개시 | HSBC Securities | Buy |
| 2025-09-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-22 | 재개 | Stephens | Overweight |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-29 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | Evercore ISI | In-line |
| 2025-02-10 | 개시 | TD Cowen | Buy |
| 2024-12-17 | 개시 | Canaccord Genuity | Hold |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 개시 | Guggenheim | Neutral |
| 2023-12-04 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 개시 | Wells Fargo | Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-03-28 | 개시 | The Benchmark Company | Buy |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2021-10-14 | 개시 | Exane BNP Paribas | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-11-01 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 개시 | SVB Leerink | Outperform |
| 2019-08-28 | 재확인 | First Analysis Sec | Outperform |
| 2019-08-23 | 재개 | Stephens | Overweight |
| 2019-07-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | 업그레이드 | CL King | Neutral → Buy |
| 2018-11-12 | 다운그레이드 | CL King | Buy → Neutral |
| 2018-09-26 | 개시 | H.C. Wainwright | Neutral |
| 2017-12-08 | 개시 | Citigroup | Buy |
| 2017-12-05 | 개시 | JP Morgan | Overweight |
| 2017-11-13 | 개시 | CL King | Buy |
| 2017-10-02 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 개시 | William Blair | Outperform |
| 2017-02-13 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
Repligen Corp 주식(RGEN)의 최신 뉴스
Wolfe Research initiates Repligen stock coverage with outperform rating By Investing.com - Investing.com Australia
Wolfe Research initiates Repligen stock coverage with outperform rating - Investing.com
Repligen Corp. Hits Day High with 8.45% Surge in Stock Price - Markets Mojo
Repligen Corp stock (US7607591002): RGEN jumps after strong Nasdaq session - AD HOC NEWS
Repligen Corp (RGEN) Stock Up 8.4% and Still Undervalued -- GF S - GuruFocus
Repligen Jumps 12% This Week as June Investor Update Approaches - Bez Kabli
Repligen (RGEN) Edges Higher Amid Bioprocessing Sector OptimismFibonacci Arc - thelegaladvocate.com
Hear Repligen's CEO give company overview at June 3 webcast - Stock Titan
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference - Yahoo Finance
Repligen Corp stock (US7607591002): ESG progress and growth focus draw fresh attention - AD HOC NEWS
Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks - Yahoo Finance
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report - Yahoo Finance
Repligen keeps factories on 100% renewable power, cuts water use 14% - Stock Titan
Repligen Corp (RGEN) Stock Up 4.2% and Still Undervalued -- GF S - GuruFocus
Repligen shares jump 4.1% as investors buy the dip after a sharp selloff; prior guidance update and short-covering may be factors - Quiver Quantitative
Repligen Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet
Why Repligen (RGEN) Stock Is Trading Up Today - Yahoo Finance
Repligen (RGEN) director granted RSUs and options in Form 4 filing - Stock Titan
Repligen (NASDAQ: RGEN) director receives new RSU and stock option awards - Stock Titan
Repligen (RGEN) director Rohin Mhatre receives RSU and option grants - Stock Titan
Repligen (RGEN) director Margaret Pax receives new RSU and stock option awards - Stock Titan
Repligen (NASDAQ: RGEN) director granted RSUs and options in equity award - Stock Titan
Repligen (RGEN) director receives new RSU and stock option grants - Stock Titan
Repligen (RGEN) director granted RSUs and stock options as compensation - Stock Titan
Repligen Corp stock (US7607591002): bioprocessing specialist back in focus after latest earnings - AD HOC NEWS
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know - Yahoo Finance
Repligen Corp stock (US7607591002): RBC upgrade and Q1 2026 earnings put bioprocessing specialist ba - AD HOC NEWS
BNY Mellon Mid Cap Multi-Strategy Fund's Repligen Corp(RGEN) Holding History - GuruFocus
Repligen Corp. 2026 Annual Meeting Results: Voting Outcomes & Key Shareholder Decisions - Minichart
Repligen shareholders approve board nominees and executive pay at annual meeting - Investing.com
Repligen (NASDAQ: RGEN) holders back board, auditor and pay plan - Stock Titan
5 Revealing Analyst Questions From Repligen’s Q1 Earnings Call - Yahoo Finance
Repligen (RGEN) Receives Positive Coverage from RBC Capital - GuruFocus
Repligen stock coverage resumed at RBC with outperform rating By Investing.com - Investing.com Nigeria
Repligen stock coverage resumed at RBC with outperform rating - Investing.com
Repligen Corp stock (US7607591002): bioprocessing specialist after earnings and 52?week low - AD HOC NEWS
Repligen CorporationCommon Stock (NQ: RGEN - FinancialContent
Repligen Corp (RGEN) Stock Down 5.8% -- Now Undervalued? GF Scor - GuruFocus
Repligen Corporation stock hits 52-week low at $109.44 - Investing.com
Repligen Opens Bioprocessing Innovation Center in the Netherlands - HarianBasis.co
Barclays Maintains an “Overweight Rating” on Repligen Corporation (RGEN) - Insider Monkey
TradingKey - TradingKey
Repligen Q1 2026 slides: revenue jumps 15%, China sales double - Investing.com
Earnings call transcript: Repligen’s Q1 2026 results exceed expectations - Investing.com
Repligen Corp at Leerink Global Healthcare Conference Transcript - GuruFocus
Repligen (RGEN) director adds 2,434 shares via option exercise - Stock Titan
Repligen (RGEN) CPO has 334 RSU shares withheld to cover taxes - Stock Titan
Investors can watch Repligen CFO live from a May 12 healthcare conference - Stock Titan
Repligen (NASDAQ: RGEN) posts Q1 2026 growth but books Polymem sale loss - Stock Titan
Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises - Yahoo Finance
Repligen Corporation (NASDAQ:RGEN) Q1 2026 Earnings Call Transcript - Insider Monkey
Repligen Corp (RGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
1.16%
자본화:
|
볼륨(24시간):